Medicare tightens DME fraud rules; smaller suppliers may struggle
H.R. 8871 — DME Scammer Prevention Act of 2026 · Filed by Aaron Bean (R-FL) · Introduced May 19, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill tightens Medicare's oversight of durable medical equipment (DME) and supplies by requiring all claims to be submitted electronically and imposing a 90-day deadline for certain items (instead of the standard longer period). It directs the Government Accountability Office to report by 2030 on how well Medicare's screening technology catches fraud and billing errors in DME claims. The bill aims to reduce waste and fraud in the DME program, which has historically been vulnerable to scams.
Why we flagged it
The bill's operative mechanism is administrative tightening—electronic submission mandates, shortened claim windows, and fraud-detection reporting—all aimed at reducing improper payments in the DME program. This is a straightforward integrity measure, not a subsidy, carve-out, or deregulation.
What the text implies
- The 90-day claim deadline may create cash-flow pressure on smaller DME suppliers and could reduce their ability to appeal denials, potentially shifting market share toward larger, better-capitalized firms with compliance infrastructure.
- Electronic submission requirements impose upfront IT costs on all DME providers; suppliers unable to invest may exit the market, reducing competition and potentially raising prices for beneficiaries in underserved areas.
The full analysis lists 3 implications of this text.
Who stands to gain
Large DME suppliers with existing electronic claims infrastructure; Medicare administrative contractors (MACs) providing screening technology; Compliance software vendors serving the DME industry